Summary

• Cencora reported Q2 results with 3.8% revenue growth and a 129% EPS increase, but shares fell sharply, apparently due to a revenue miss.
• Despite a forward P/E of ~14 and manageable debt, COR faces thin margins, client concentration risks, and headwinds from biosimilars and drug price reductions.
• Management remains confident, targeting $3B in free cash flow and $1B in share repurchases for 2026, with ongoing M&A to expand specialty services.
• I view the recent sell-off as an overreaction, presenting a 'buy the dip' opportunity given COR's robust fundamentals and undervaluation.
• Looking for higher risk/reward options trading ideas? I offer this and much more at my exclusive investing ideas service, Haggerston BioHealth. Learn More »

Investment Overview

Cencora, Inc. (COR), the Pennsylvania-headquartered pharmaceutical sourcing and distribution services company, reported its fiscal year 2026 second-quarter results yesterday, prompting a fall in its share price from >$305 per share to ~$250.

The company earned revenues of $78.4bn, up 3.8% year-on-year, and reported gross profit of $3.6bn, up 17%, and operating income of $1.1bn, up 10% year-on-year. Diluted earnings per share increased by 129% year-on-year to $8.4. Guidance for the full year 2026 was provided as per the slide below (taken from Cencora's earnings presentation):

Analysis: Why Did The Market Punish An Apparently Strong Set Of Results?

Cencora - formerly known as Amerisource Bergen - is valued at a market cap of $49bn today, meaning its forward price-to-sales ("P/S") ratio, based on 2026 full-year revenue guidance of ~$337.4bn at the midpoint, is ~0.15x.

That is a shockingly low figure - I doubt many businesses generating revenues in the triple-digit billions can match it - which usually indicates a business is in some kind of trouble - over-burdened with debt and on the brink of collapse, for example, or losing tens of billions of dollars per annum.

Cencora, however, trades at a forward price-to-earnings ratio of ~14, which is another positive metric - this is a reasonably profitable business - while its level of debt does not seem onerous, either. Long-term debt stands at just over $12bn; according to Seeking Alpha, the current portion of long-term debt stands at ~$203m, and cash and equivalents stand at ~$2.2bn.

The issue that Wall Street seems to have had with Cencora's earnings is that revenues fell short of expectations (although Cencora still bet on EPS), and as we can see in the table above, they were down sequentially by >$7bn, although seemingly, this is not untypical for this particular quarter.

The last

14.95K Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.